Frontier drug discovery programs require frontier capabilities. Today, we’re... excited to share that BMS will be using Chai’s models to support the discovery of new therapeutics. Since rolling out Chai-3 to partners at the start of this year, we’ve partnered with Eli Lilly and Company, Novartis, Pfizer Inc., argenx, and now Bristol Myers Squibb. Many of the world’s leading biopharma companies are now using our models to go after diseases. Scientific discovery is the domain where access to frontier AI matters the most. At Chai Discovery, we’ve seen first hand how our latest model generations can make the difference between discovering a molecule and not. We’re excited to work with Bristol Myers Squibb to break new ground in medicine and science.show more

Today at GTC, we’re excited to announce our collaboration... with Bristol Myers Squibb to bring the latest Boltz models into BMS’s drug discovery workflows. Bristol Myers Squibb Boltz 🚀🧵show more

2025 = breakthrough research in AI for drug discovery;... 2026 = the year of deployment at scale. Today we share that @ChaiDiscovery is partnering with Eli Lilly and Company to accelerate biologics discovery.show more

Excited to announce our partnership with dsm-firmenich to bring... Boltz's latest AI models to the discovery and design of new scent and flavor molecules! 🧪show more

We’re proud to share that Tamarind Bio has been... selected to build, host, and operate the inference infrastructure layer for TuneLab2.0, the next evolution of the platform. Eli Lilly and Company TuneLab is a first-of-its-kind, collaborative AI/ML drug discovery platform, bringing models trained on over $1B worth of Lilly proprietary data to the biotech ecosystem. Tamarind will power TuneLab’s scalable drug discovery workflows and model inference.show more

Scientific breakthroughs demand infrastructure that performs at the highest... level. From Frontier, the world’s fastest supercomputer, to LUMI and Discovery, AMD and HPE bring supercomputing design and high-performance compute together to help researchers push boundaries in climate science, drug discovery, fusion energy, and AI. See how the most trusted companies trust AMD:show more

Today we are announcing our collaboration with Pfizer to... put Chai's frontier AI—including our latest model, Chai-3—directly into the hands of one of the world's leading pharmaceutical teams.show more

Today marks the start of a new program where... global pharmaceutical companies are coming together to collaborate... but why? Let’s take a closer look ⬇️ AstraZeneca | Bristol Myers Squibb |GSK | Johnson & Johnson | Pfizer Inc. | Sanofishow more

Join us in the run-up to the release of... our music program per day, which we'll share today at 15:00. But first, let us extend our discovery. We’re adding nine new names to our program. From new and exciting, to experienced and brilliant, check it out now, with more to come.show more

We've been defining the actual frontier of AI for... science: - created the most powerful agents and generative models of our biomolecular world - coupled with the most accurate models of state - proved again and again ability to break novel ground in drug design >>> now I'm looking for those who want to push frontier LLMs even further, in an environment where you see the impact on real science the next day 1/2show more

Today we're dropping the "beta" tag from Adaptyv, launching... our new website and announcing our $8M seed round. When we started Adaptyv a few years ago, our core belief was: AI models for biology are only as good as the experimental data they're trained on and the hypotheses they can test in the real world. Now, after a year of working with many great partners, we’ve scaled our infrastructure to the point that we're now open to anyone who wants to use our platform! Overall, this year, over 30 companies started using Adaptyv to validate their protein designs - from some of the biggest pharmas to frontier AI labs to many, many techbio startups. We've run hundreds of experiments, tested well over 10,000 proteins this year and are generating the data that validates the best AI models currently in development.show more

I'm delighted to announce a new collaboration between @ChaiDiscovery... & Novartis. It's been a pleasure working together over the past year, and we're excited to scale our collaboration to support broader deployment of Chai-3 across multiple therapeutic programs.show more

We’re delighted to announce our third agreement this week,... this time a collaboration with argenx. argenx has built one of biotechnology’s most productive antibody engines. We’ll be putting Chai’s frontier molecular design platform into the hands of their scientists.show more

The future of drug discovery is here. Formation Bio... is joining our Billion Cell Atlas program to help redefine what’s possible in AI-driven drug development, advancing the next generation of therapeutics. By addressing key bottlenecks across the drug discovery continuum, the Atlas can help accelerate the journey from biological insights to approved drugs — bringing greater precision to how we understand what works, why it works, and which patient populations are most likely to benefit. Together, we’re helping bring more precision medicines to life and reimagine what’s possible in biology. Discover the next era:show more

The frontier of world models and agents is overwhelmingly... in Europe. Kyutai is excited to partner with General Intuition General Intuition to continue pushing that edge through open science.show more

Open, permissionless science moves the world forward. Part of... our vision Bio Protocol involves the use of autonomous scientific agents to accelerate the pace of discovery in biology. We're excited to share our new framework for developing & deploying BioAgents. 👇 🤖 🧬show more

Next Frontier: Predictions 📈 Our goal is for MobyScreener... to become the home for all types of onchain discovery. We started by reshaping token discovery with MobyScreener and Whale Watch by Moby Now, we’re expanding into Prediction Markets with the launch of Smart Money Feeds natively on This live feed tracks the top traders on Polymarket, showing you exactly what they’re buying and selling in real time. Our algorithm identifies the most profitable bettors onchain and surfaces their trades in a clean, actionable UI. Smart Money Feeds is just the beginning of a new wave of features designed to transform how traders win with Prediction Markets.show more

AI has two modes in drug discovery. Accelerate: moving... faster through the existing playbook. Unlock: opening frontiers that weren't possible before. Excited to announce Profluent is partnering with Eli Lilly, the global pharma powerhouse, to unlock breakthrough medicines for patients. It's a big deal beyond the numbers ($2.25B + royalties): we’ll get to use our frontier AI models and foundational datasets to design proteins focused on large gene insertion, a therapeutic moonshot. Proteins govern almost everything in biology. We've built a generalizable AI platform to design all proteins. Onward!show more

1 billion cells. One atlas. Today, Illumina introduces the... Billion Cell Atlas, creating the most comprehensive map of human disease biology — and unlocking unparalleled speed and scale in AI for drug discovery. The Atlas will help researchers, including founding participants AstraZeneca, Merck, and Eli Lilly and Company study the effect of switching on and off all 20,000 genes in cells linked to diseases that have been historically difficult to decode. Learn how the Atlas will elucidate the biological pathways behind some of the world’s most devastating diseases: #JPM2026show more

Introducing Rothko, a foundation model of human behaviour designed... from the ground up to simulate the world’s most consequential decisions. Rothko is the result of over three years of frontier research at the intersection of behavioural science and machine learning. We’re only just starting to uncover the model’s value across domains ranging from market research to AI safety and swarm alignment.show more

Today we’re releasing SAIR, the Structurally Augmented IC50 Repository.... SAIR is the Largest Open-Sourced Binding Affinity Dataset with Cofolded 3D Structures. It includes more than 5 million protein-ligand structures, generated using our Large Quantitative Models and labeled with binding affinity data. By providing this unprecedented scale of structure-activity data, we aim to enable researchers to train and evaluate new AI models for drug discovery, bridging the historical gap between molecular structures and drug potency prediction. The SAIR dataset was created using the NVIDIA DGX Cloud and is now publicly available on the Google Cloud Platform. Access and build with SAIR today! 📰Read the Press Release: 📥Learn More and Download the Dataset at #DrugDiscovery #LQMs #SAIR #AIforScience #SandboxAQshow more